Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Motyl

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
BMC Microbiology|July 6, 2019
In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosaKatherine Young, Ronald E Painter, Susan L Raghoobar, et al.
Scientific Reports|July 21, 2017
Genomic epidemiology of global Klebsiella pneumoniae carbapenemase (KPC)-producing Escherichia coliN Stoesser, A E Sheppard, G Peirano, et al.
Journal of Medical Microbiology|April 22, 2022
Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019James A Karlowsky, Sibylle H Lob, Aaron Khan, et al.
Diagnostic Microbiology and Infectious Disease|May 7, 2011
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteriaMichael A Pfaller, David Andes, Maiken C Arendrup, et al.
Journal of Global Antimicrobial Resistance|April 22, 2023
Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020James A Karlowsky, Sibylle H Lob, Tsz K Khan, et al.
Journal of Clinical Microbiology|August 21, 2009
Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methodsM A Pfaller, D J Diekema, M A Ghannoum, et al.
Lancet (London, England)|February 7, 2021
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trialJohan A Maertens, Galia Rahav, Dong-Gun Lee, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 2, 2016
New Antimicrobial Agents  …  but No Susceptibility Tests!Jane E Ambler, Kevin M Krause, Judith N Steenbergen, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
BMC Microbiology|July 6, 2019
In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosaKatherine Young, Ronald E Painter, Susan L Raghoobar, et al.
Scientific Reports|July 21, 2017
Genomic epidemiology of global Klebsiella pneumoniae carbapenemase (KPC)-producing Escherichia coliN Stoesser, A E Sheppard, G Peirano, et al.
Journal of Medical Microbiology|April 22, 2022
Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019James A Karlowsky, Sibylle H Lob, Aaron Khan, et al.
Diagnostic Microbiology and Infectious Disease|May 7, 2011
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteriaMichael A Pfaller, David Andes, Maiken C Arendrup, et al.
Journal of Global Antimicrobial Resistance|April 22, 2023
Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020James A Karlowsky, Sibylle H Lob, Tsz K Khan, et al.
Journal of Clinical Microbiology|August 21, 2009
Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methodsM A Pfaller, D J Diekema, M A Ghannoum, et al.
Lancet (London, England)|February 7, 2021
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trialJohan A Maertens, Galia Rahav, Dong-Gun Lee, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 2, 2016
New Antimicrobial Agents  …  but No Susceptibility Tests!Jane E Ambler, Kevin M Krause, Judith N Steenbergen, et al.
Pageof 8